Definition

Accumulation of chyle (lymphatic fluid) in the pleural space due to leakage from the thoracic duct or its tributaries. The thoracic duct transports approximately 4 litres of chylous lymph per day — large-volume chyle leaks cause rapid nutritional depletion, immunological compromise, and haemodynamic instability.

Thoracic duct anatomy

The thoracic duct begins at the cisterna chyli (L1–L2) and ascends through the aortic hiatus. It runs in the posterior mediastinum between the aorta (left) and azygos vein (right), crossing from right to left at T5–T6. It drains into the left subclavian-internal jugular venous angle. Anatomical variation is common — awareness prevents inadvertent injury during oesophageal, mediastinal, and spinal surgery.

Surgical relevance — iatrogenic injury

The thoracic duct is at risk during: oesophagectomy (right thoracic approach), left pneumonectomy, posterior mediastinal tumour excision, radical neck dissection, PDA ligation, coarctation repair, and retroperitoneal node dissection. Routine mass ligation of all tissue above the aortic hiatus during oesophagectomy prevents post-operative chylothorax.

Aetiology

Aetiology of chylothorax
CategoryCauses
Non-traumatic (most common)
NeoplasticLymphoma (accounts for up to two-thirds of all chylothorax) · sarcoma · lung cancer
MiscellaneousTB · filariasis · retroperitoneal fibrosis
Traumatic / iatrogenic
Thoracic surgeryLeft pneumonectomy · oesophagectomy · posterior mediastinal tumour excision
Cardiac surgeryPDA ligation · coarctation repair · CABG
Neck surgeryRadical neck dissection
Abdominal surgeryRetroperitoneal lymph node dissection · lumbar sympathectomy
Diagnostic proceduresCentral venous cannulation · lumbar arteriography
TraumaBlunt and penetrating chest injuries
Congenital
Birthing trauma · lymphatic malformation · idiopathic

Diagnosis

Chylothorax is confirmed by pleural fluid analysis. The classic appearance is milky-white fluid that does not clear with centrifugation. Triglyceride level >110 mg/dL with chylomicrons on lipoprotein electrophoresis is diagnostic. Distinguish from pseudochylothorax (cholesterol effusion from long-standing empyema or RA):

Chylothorax vs pseudochylothorax — pleural fluid differences
ParameterChylothoraxPseudochylothorax
Triglycerides>110 mg/dL<50 mg/dL
Cholesterol<200 mg/dL>200 mg/dL
Cholesterol crystalsAbsentPresent
ChylomicronsPresentAbsent
Clinical contextAcute; usually normal pleuraChronic; thickened pleura (RA, TB)

Lymphangiography / lymphoscintigraphy: Defines thoracic duct anatomy and identifies the leak site when surgery is planned. Useful when the site of leakage is not clinically obvious.

Treatment

Conservative management (first-line)

Approximately 50% of chyle leaks — particularly small traumatic leaks — resolve spontaneously with conservative measures over 2–4 weeks.

Non-surgical management of chylothorax
InterventionDetails
Pleural drainageIntercostal drain or repeated thoracentesis — reduces chyle accumulation
Nutritional supportFat-restricted diet with MCT supplementation (MCTs absorbed directly into portal circulation, bypassing the thoracic duct) · TPN to rest the duct in high-volume leaks
Somatostatin / octreotideReduces lymphatic flow by 30–40%; useful adjunct to drainage

Surgical treatment

Indications for surgery:

  • Chyle leak >1500 mL/day in adults or >100 mL/day per year of age in children
  • Persistent leak for >2 weeks despite conservative management
  • Nutritional or metabolic complications despite TPN
  • Post-oesophagectomy chylothorax (early surgery preferred)
Gold standard — thoracic duct ligation

Mass ligation of all tissue between the aorta and azygos vein just above the aortic hiatus (T8–T12) — performed via right chest (thoracoscopic or open). This eliminates the need to identify the individual duct and ligates all tributaries. Cream or olive oil given via NG tube 2–3 hours pre-operatively makes the duct more visible and engorged intraoperatively.

Alternative procedures:

  • Thoracoscopic parietal pleural clipping — if the site of leak is identified
  • Lymphatic embolisation with fibrin glue — under fluoroscopic guidance for poor surgical risk
  • Pleuroperitoneal shunt, pleurodesis, or pleurectomy — for refractory or malignant cases
Further reading

All clinical content should be verified against current guidelines before clinical application. This resource is intended for revision and educational purposes only.

Standard textbooks

  • Shields TW, LoCicero J, Reed CE, Feins RH. General Thoracic Surgery. 7th ed. Lippincott Williams & Wilkins.
  • Sellke FW, del Nido PJ, Swanson SJ. Sabiston & Spencer Surgery of the Chest. 9th ed. Elsevier.
  • Pearson FG, et al. Thoracic Surgery. 3rd ed. Churchill Livingstone.

Current guidelines & resources